Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the ...

TransCode Therapeutics, in partnership with Quantum Leap Healthcare Collaborative, has submitted an IND application amendment ...

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.

Nektar will now take Treg therapy, rezpeg to a Phase III trial in atopic dermatitis (AD), which is set to begin in Q2 2026.

The impact of Covid-19 pandemic included various downstream effects on health endpoints worldwide, including the increase in substance abuse.

Compass plans to submit a NDA for its psilocybin-based psychedelic, COMP360 in TRD during Q4 2026. Credit: AnastasiaNi/Shutterstock.com. Compass Pathways’ stock is ...

Sanofi and Teva are already investigating the drug in Phase III trials in UC and CD. Image credit: Jo Panuwat D / Shutterstock.com Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown ...

JANX011 targets CD19-expressing B cells in blood and tissues for deep, lasting immune reset in autoimmune disease treatment. Credit: Asian Isolated / Shutterstock.com. Janux Therapeutics has dosed the ...

With ramping complexity, technology plays a key role in managing the clinical supply chain. Image credit: Corona Borealis Studio via Shutterstock Clinical development has fundamentally changed, yet ...

Pfizer will be speaking with authorities about the combination following the Phase III readout. Photo by SOPA Images/LightRocket via Getty Images. Another of Pfizer’s Braftovi regimens has shown ...